A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
Phase 1
Completed
NCT03374241
| Condition | Obesity |
|---|
| Phase | Phase 1 |
|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
|---|
| Status | Completed |
|---|
| Enrollment | 41 participants |
|---|
| Interventions | HM15211 or Placebo |
|---|
| Start date | Apr 4, 2018 |
|---|
| Completion date | Sep 14, 2018 |
|---|
| Results posted | May 17, 2024 |
|---|
Summary
Single ascending dose of HM15211 in healthy obese subjects.
Number of Participants With Adverse Events
1 month · Participants
| Cohort 1 Active | 3 Participants |
|---|
| Cohort 2 Active | 2 Participants |
|---|
| Cohort 3 Active | 3 Participants |
|---|
| Cohort 4 Active | 7 Participants |
|---|
| Cohort 5 Active | 4 Participants |
|---|
| Placebo | 7 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.